Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.
Key speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
Quantum-Si (Nasdaq: QSI), La Società di Sequenziamento delle Proteine™, ha annunciato la sua partecipazione a un prossimo webinar di DNAnexus incentrato sulla proteomica nella ricerca multi-omica. L'evento virtuale, programmato per 25 marzo 2025, alle 8:00 PT/11:00 ET, esplorerà come l'integrazione dei dati proteomici con altri set di dati omici possa portare a nuove scoperte nella ricerca sulle malattie, incluso il cancro.
I relatori principali includono Meredith Carpenter, PhD di Quantum-Si, Cindy Lawley, PhD di Olink, Thermo Fisher Scientific, e Theresa Wohlever di DNAnexus. Il webinar tratterà:
- L'impatto crescente della proteomica nell'analisi multi-omica
- Applicazioni per la ricerca sul cancro e altre malattie
- Tecnologie e strategie per la scoperta su larga scala e l'analisi dei dati
- Strumenti per la validazione ortogonale delle proteine di interesse
Quantum-Si (Nasdaq: QSI), La Compañía de Secuenciación de Proteínas™, ha anunciado su participación en un próximo webinar de DNAnexus centrado en la proteómica en la investigación multi-ómica. El evento virtual, programado para 25 de marzo de 2025, a las 8 a.m. PT/11 a.m. ET, explorará cómo la integración de datos proteómicos con otros conjuntos de datos ómicos impulsa nuevos descubrimientos en la investigación de enfermedades, incluido el cáncer.
Los ponentes principales incluyen a Meredith Carpenter, PhD de Quantum-Si, Cindy Lawley, PhD de Olink, Thermo Fisher Scientific, y Theresa Wohlever de DNAnexus. El webinar cubrirá:
- El creciente impacto de la proteómica en el análisis multi-ómico
- Aplicaciones para la investigación del cáncer y otras enfermedades
- Tecnologías y estrategias para el descubrimiento y análisis de datos a gran escala
- Herramientas para la validación ortogonal de proteínas de interés
Quantum-Si (Nasdaq: QSI), 단백질 서열 분석 회사™, 는 다중 오믹스 연구에서 단백질체학에 중점을 둔 DNAnexus 웨비나에 참여할 것이라고 발표했습니다. 2025년 3월 25일 오전 8시 PT/오후 11시 ET에 예정된 이 가상 이벤트는 단백질체학 데이터를 다른 오믹스 데이터 세트와 통합하여 질병 연구, 특히 암 연구에서 새로운 발견을 이끌어내는 방법을 탐구할 것입니다.
주요 연사로는 Quantum-Si의 Meredith Carpenter, PhD, Olink, Thermo Fisher Scientific의 Cindy Lawley, PhD, 그리고 DNAnexus의 Theresa Wohlever가 있습니다. 웨비나는 다음과 같은 내용을 다룰 것입니다:
- 다중 오믹스 분석에서 단백질체학의 증가하는 영향
- 암 및 기타 질병 연구를 위한 응용 프로그램
- 대규모 발견 및 데이터 분석을 위한 기술과 전략
- 관심 있는 단백질의 정량적 검증을 위한 도구
Quantum-Si (Nasdaq: QSI), La Société de Séquençage des Protéines™, a annoncé sa participation à un prochain webinaire de DNAnexus axé sur la protéomique dans la recherche multi-omique. L'événement virtuel, prévu pour le 25 mars 2025, à 8h PT/11h ET, explorera comment l'intégration des données protéomiques avec d'autres ensembles de données omiques peut conduire à de nouvelles découvertes dans la recherche sur les maladies, y compris le cancer.
Les intervenants principaux comprennent Meredith Carpenter, PhD de Quantum-Si, Cindy Lawley, PhD d'Olink, Thermo Fisher Scientific, et Theresa Wohlever de DNAnexus. Le webinaire couvrira :
- L'impact croissant de la protéomique dans l'analyse multi-omique
- Applications pour la recherche sur le cancer et d'autres maladies
- Technologies et stratégies pour la découverte à grande échelle et l'analyse de données
- Outils pour la validation orthogonale des protéines d'intérêt
Quantum-Si (Nasdaq: QSI), Das Unternehmen für Proteinsequenzierung™, hat seine Teilnahme an einem bevorstehenden DNAnexus-Webinar angekündigt, das sich auf Proteomik in der Multi-Omics-Forschung konzentriert. Die virtuelle Veranstaltung, die für 25. März 2025, 8 Uhr PT/11 Uhr ET geplant ist, wird untersuchen, wie die Integration von Proteomik-Daten mit anderen Omics-Datensätzen neue Entdeckungen in der Krankheitsforschung, einschließlich Krebs, vorantreibt.
Zu den Hauptrednern gehören Meredith Carpenter, PhD von Quantum-Si, Cindy Lawley, PhD von Olink, Thermo Fisher Scientific, und Theresa Wohlever von DNAnexus. Das Webinar wird folgende Themen behandeln:
- Die wachsende Bedeutung der Proteomik in der Multi-Omics-Analyse
- Anwendungen für Krebs- und andere Krankheitsforschung
- Technologien und Strategien für groß angelegte Entdeckungen und Datenanalysen
- Werkzeuge zur orthogonalen Validierung von interessierenden Proteinen
- None.
- None.
Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™
When: March 25, 2025, at 8 a.m. PT/11 a.m. ET
Attendees will learn about:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
WHO: Featured speakers include:
- Meredith Carpenter, PhD, Head of Scientific Affairs, Quantum-Si
- Cindy Lawley, PhD, Sr. Director, Population Health Proteomic Sciences, Olink, Thermo Fisher Scientific
- Theresa Wohlever, Sr. Bioinformatics Scientist, DNAnexus
WHERE: Virtual event – registration required.
HOW: To register, please complete the registration form. A confirmation email will be sent upon registration.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320735438/en/
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated